A Pilot Study to Assess the Effect of Intermittent iNO on the Treatment of NTM Lung Infection in CF and Non-CF Patients

Inclusion Criteria: * Subjects diagnosed with refractory NTM (MAC or MAbs) pulmonary infection * CF and Non-CF patients Exclusion Criteria: * Diagnosis of methemoglobinemia or MetHb ≥2% at screening; treatment with any drug known to increase MetHb; known or suspected hemoglobinopathy. * History of or current myeloproliferative disease, leukemia or other hematological malignancy; known or suspected immunodeficiency disease. * Subjects with advanced cardiovascular disease or CHF * Use of an investigational drug during the 30 days prior to enrollment. * History of frequent epistaxis (\>1 episode/month); significant hemoptysis (during the 30 days prior to enrollment. * Subject on non-constant dose of systemic steroids within 30 days prior to enrollment; subjects on constant systemic steroids if the daily dose is higher than 10 mg/d prednisolone or equivalent. * Active pulmonary malignancy (primary or metastatic) or any malignancy; history of lung transplantation. * Pulmonary tuberculosis requiring treatment or treated within 2 years prior to screening. * Uncontrolled hypertension within 3 months prior to or at screening * Diagnosis of significant pulmonary hypertension indicated on echocardiogram at screening * Clinically significant renal or liver laboratory abnormalities * History of daily, continuous oxygen supplementation. * Women of childbearing potential - pregnant or breastfeeding, or not on medically acceptable double methods of contraception from enrollment until Day 84. * Smoking tobacco or any substance within 6 months prior to screening or anticipated inability to refrain from smoking throughout the study. * Patient receiving drugs that have a contraindication with NO